Cotierra raises $3 Million to scale decentralised biochar systems
Swiss biochar company Cotierra has raised $3 million in a new funding round as it looks to take its decentralised biocha…
Australia advances multibreed genetic evaluation for beef cattle
Australian beef producers, breeders and industry stakeholders can now access a dedicated online resource explaining the …
Expana launches Expana IQ Connect to bring trusted agrifood intelligence into enterprise AI
The next battleground for enterprise AI may not be the model itself, but the quality of the data feeding it. Expana is m…
Researchers identify four policy bottlenecks holding back bio-breeding in China
Biotechnology-based breeding could help improve crop resilience, resource-use efficiency and reduce dependence on chemic…
Vittia secures R$153 Million as Brazil’s biologicals market enters new phase
Brazilian biologicals company Vittia has secured up to R$153 million ($26.8 million) in financing from Finep, Brazil’s i…
Philippines prepares P45 Billion El Niño response as food prices accelerate
The Philippines is stepping up efforts to protect food supplies and contain prices as a combination of weather disruptio…
China’s new oilseed rape variety delivers record yield in high-altitude trial
A new spring oilseed rape variety developed by the Oil Crops Research Institute of the Chinese Academy of Agricultural S…
Vylor completes Spin, launches as standalone, advanced seed and genetics market leader
Vylor has begun trading as an independent, publicly listed seed and genetics company, completing its separation from Cor…
ADC Therapeutics buys time for Zynlonta with $86.6M financing
The Lausanne-based company plans to use the financing to support further development of its lymphoma drug Zynlonta, including Phase 3 studies combining it with glofitamab in diffuse large B-cell lymphoma and testing it alone in marginal zone lymphoma.
Another bad day at Zealand: Roche-partnered drug disappoints on blood sugar
Why it matters: Zealand and Roche are betting that petrelintide’s tolerability can distinguish it in the crowded obesity market. The latest results strengthen that argument, but raise questions about its competitiveness as a standalone treatment for people who also have type 2 diabetes.